All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

diiodohydroxyquinoline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
quinoline derivatives	1457	83-73-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: iodoquinol diiodohydroxyquinoline diiodohydroxyquin diiodoquin diiodoquinol	One of the halogenated 8-quinolinols widely used as an intestinal antiseptic, especially as an antiamebic agent. It is also used topically in other infections and may cause CNS and eye damage. It is known by very many similar trade names world-wide. Molecular weight: 396.95 Formula: C9H5I2NO CLOGP: 4.14 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 33.12 ALOGS: -3.69 ROTB: 0

Drug dosage:

Dose	Unit	Route
0.20	g	V

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	8 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	4.107		Moderate	0.71
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.303		Moderate	0.71
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	14.689	10^-6 cm/s	Moderate	0.71
dh-clint	Dog hepatocyte intrinsic clearance	148.936	uL/min/10^6 cells	Moderate	0.71
dppb	Dog plasma protein binding (% unbound)	0.170	%	Moderate	0.71
fcs-ppb	Fetal calf serum protein binding (% unbound)	0.240	%	Moderate	0.71
herg	hERG pIC50	4.702	pIC50	Moderate	0.71
hh-clint	Human hepatocyte intrinsic clearance	100.462	uL/min/10^6 cells	Moderate	0.71
hlm-clint	Human liver microsomal intrinsic clearance	34.995	uL/min/mg protein	Moderate	0.71
hppb	Human plasma protein binding (% unbound)	0.380	%	Moderate	0.71
kinase-safety-class	ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK2,CDK4,CDK5,CDK7,CDK9,CHEK1,CLK4,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3A,GSK3B,IKBKB,IRAK1,ITK,JAK1,JAK2,JAK3,KDR,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PLK1,PRKAA1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TTK,UHMK1,ULK1,ULK2,ZAP70	92
kinase-selectivity-class	ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,GRK2,GSK3B,MAP2K1,MAP2K3,MAP2K6,MAPK1,MAPK12,MAPK7,MARK4,PIK3CB,PRKDC,SIK2,STK33,SYK,TEK,TTK,ULK1	27
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	0.242		Moderate	0.71
mh-clint	Mouse hepatocyte intrinsic clearance	483.059		Moderate	0.71
mppb	Mouse plasma protein binding (% unbound)	0.370		Moderate	0.71
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	0.072		Moderate	0.71
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	0.200	%	Moderate	0.71
rh-clint	Rat hepatocyte intrinsic clearance	338.065	uL/min/10^6 cells	Moderate	0.71
rh-fuinc	Rat hepatocyte fraction unbound in incubation	4.440	%	Moderate	0.71
rppb	Rat plasma protein binding (% unbound)	0.120	%	Moderate	0.71
solubility-dd	Solubility at pH 7.4 in DMSO	1.156	uM	Moderate	0.71

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G01AC01	GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Quinoline derivatives
MeSH PA	D000563	Amebicides
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
CHEBI has role	CHEBI:33282	antibacterial agent
CHEBI has role	CHEBI:35820	antiprotozoal drug
CHEBI has role	CHEBI:48218	antiseptic drug
CHEBI has role	CHEBI:171664	antiamoebic agent

Related Drugs by ATC class:

G01AC Quinoline derivatives 5 drugs

broxyquinolinechlorquinaldolclioquinoldequaliniumoxyquinoline

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Amebic infection	indication	111910009	DOID:9181
Atopic dermatitis	off-label use	24079001	DOID:3310
Contact dermatitis	off-label use	40275004	DOID:2773
Lichen simplex chronicus	off-label use	53891004
Pruritus ani	off-label use	90446007
Pruritus of genital organs	off-label use	267802000
Eruption of skin	off-label use	271807003	DOID:0050486
Optic neuritis	contraindication	66760008	DOID:1210
Disease of liver	contraindication	235856003	DOID:409
Telangiectasia disorder	contraindication	247479008
Peripheral nerve disease	contraindication	302226006
Adrenal cortical hypofunction	contraindication	386584007	DOID:10493
Atrophoderma	contraindication	399979006
Peripheral vascular disease	contraindication	400047006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.61	acidic
pKa2	2.03	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Adenosine receptor A3	GPCR	P0DMS8	AA3R_HUMAN		Ki	6.28		DRUG MATRIX
Epidermal growth factor receptor	Kinase	P00533	EGFR_HUMAN		IC50	5.72		DRUG MATRIX
Tyrosine-protein kinase Lck	Kinase	P06239	LCK_HUMAN		IC50	5.61		DRUG MATRIX
Tyrosine-protein kinase Fyn	Kinase	P06241	FYN_HUMAN		IC50	5.80		DRUG MATRIX
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN		IC50	5.07		DRUG MATRIX
Mitogen-activated protein kinase 3	Kinase	P27361	MK03_HUMAN		IC50	5.28		DRUG MATRIX
Mitogen-activated protein kinase 14	Kinase	Q16539	MK14_HUMAN		IC50	6.44		DRUG MATRIX
Mitogen-activated protein kinase 1	Kinase	P28482	MK01_HUMAN		IC50	6.53		DRUG MATRIX
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	6.04		DRUG MATRIX
Catechol O-methyltransferase	Enzyme		COMT_RAT		IC50	5.25		CHEMBL
Beta-lactamase NDM-1	Enzyme		BLAN1_KLEPN		IC50	5.60		CHEMBL

External reference:

ID	Source
4018600	VUID
N0000146916	NUI
D00581	KEGG_DRUG
4018600	VANDF
C0012341	UMLSCUI
CHEBI:5950	CHEBI
CHEMBL86754	ChEMBL_ID
DB09115	DRUGBANK_ID
3728	PUBCHEM_CID
3435	RXNORM
2439	MMSL
4903	MMSL
d01105	MMSL
002952	NDDF
387355005	SNOMEDCT_US
64851009	SNOMEDCT_US
D004103	MESH_DESCRIPTOR_UI
1613	INN_ID
63W7IE88K8	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Vytone	HUMAN PRESCRIPTION DRUG LABEL	2	44118-704	CREAM	10 mg	TOPICAL	unapproved drug other	9 sections
HYDROCORTISONE, IODOQUINOL	HUMAN PRESCRIPTION DRUG LABEL	2	52187-532	CREAM	10 mg	TOPICAL	unapproved drug other	11 sections
Hydrocortisone Acetate, Iodoquinol	HUMAN PRESCRIPTION DRUG LABEL	2	52187-551	CREAM	10 mg	TOPICAL	unapproved drug other	9 sections
Alcortin	HUMAN PRESCRIPTION DRUG LABEL	2	68040-702	GEL	1 g	TOPICAL	unapproved drug other	2 sections
Alcortin A	HUMAN PRESCRIPTION DRUG LABEL	3	68040-705	GEL	10 mg	TOPICAL	UNAPPROVED OTHER	17 sections
Aloquin	HUMAN PRESCRIPTION DRUG LABEL	2	68040-706	GEL	12.50 mg	TOPICAL	Unapproved other	15 sections
IODOQUINOL HYDROCORTISONE ACETATE ALOE POLYSACCHARIDES	HUMAN PRESCRIPTION DRUG LABEL	3	72056-020	GEL	10 mg	TOPICAL	UNAPPROVED DRUG OTHER	17 sections
HYDROCORTISONE IODOQUINOL	HUMAN PRESCRIPTION DRUG LABEL	2	72056-040	CREAM	10 mg	TOPICAL	Unapproved drug other	17 sections
HYDROCORTISONE 2.5% / IODOQUINOL 1% / KETOCONAZOLE 2%	HUMAN PRESCRIPTION DRUG LABEL	3	72934-2111	CREAM	1 g	TOPICAL	unapproved drug other	4 sections